The Risks, Benefits, and Uncertainties of Stepping Down Asthma Medications
Authors:
- 1 September 2014
- journal article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 2 (5) , 503-509
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- The Optimal Practice of Evidence-Based MedicineJAMA, 2013
- Inhaled Corticosteroids and the Risk of Pneumonia in People With AsthmaChest, 2013
- Full Disclosure — Out-of-Pocket Costs as Side EffectsNew England Journal of Medicine, 2013
- Effect of Inhaled Glucocorticoids in Childhood on Adult HeightNew England Journal of Medicine, 2012
- Supervised step-down of inhaled corticosteroids in the community – An observational studyRespiratory Medicine, 2011
- The FDA and Safe Use of Long-Acting Beta-Agonists in the Treatment of AsthmaNew England Journal of Medicine, 2010
- AsthmaNew England Journal of Medicine, 2009
- Maintaining asthma control in persistent asthma: Comparison of three strategies in a 6-month double-blind randomised studyRespiratory Medicine, 2008
- Deterioration in Asthma Control When Subjects Receiving Fluticasone Propionate/Salmeterol 100/50 mcg Diskus are “Stepped-Down”Journal of Asthma, 2008
- Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costsPrimary Care Respiratory Journal, 2005